Tivic Health. We are an immunotherapeutics company.
Our science focuses on restoring the healthy function of the immune system. Our late-stage, highly de-risked Entolimod™ asset is a first-in-class host-protection platform. Based on its mechanism of action, Entolimod™ shows promise for reducing severe treatment-limiting toxicities thereby potentially creating highly differentiated treatments across military, oncology, and age-related indications.
A message from our CEO
Tivic has entered a transformative new era focused on high-growth biopharma opportunities as well as a state-of-the-art biomanufacturing facility that provides mission-critical services to other biotech companies and puts us in control of our own supply chain.
The company’s high value pipeline of immunomodulation drug candidates has the potential to treat disease states that range from a military countermeasure to treat acute radiation syndrome to oncology-related indications including Neutropenia, a debilitating side effect of radiation treatments.
With Entolimod’s and Entolasta’s ability to activate a well-characterized immune pathway to prevent cell death and protect cell regeneration mechanisms, we are well positioned to deliver profound value to patients with critical unmet medical need.
– Michael K. Handley, CEO Tivic
Latest Presentation
Latest Press Releases
Events
